End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12,830 KRW | -4.25% | -3.90% | -43.85% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-43.85% | 150M | - | ||
-1.71% | 14.91B | - | ||
-34.43% | 2.96B | C- | ||
-13.40% | 2.41B | - | ||
-12.18% | 1.48B | - | - | |
-.--% | 1.12B | - | - | |
+60.60% | 583M | - | ||
+13.87% | 244M | C | ||
+0.70% | 230M | - | - | |
+7.22% | 188M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- A228670 Stock
- Ratings Ray Co., Ltd.